Previous 10 | Next 10 |
The Premium Portfolio has gained +6.80% YTD compared to the S&P 500 +21.62% YTD and the Aurum Hedge Fund Industry Index +6.31% with one week to go. The Premium Portfolio compound annual growth rate (CAGR) of +25.57% compares favorably to the S&P 500 of +14.31% CAGR from 2018. ...
Cara Therapeutics (NASDAQ:CARA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) greenlighted a form of reimbursement for KORSUVA (difelikefalin) injection in the anti-pruritic functional category. The Transitional Drug Add-On Payment Adjustment (TDAPA) issued for KO...
KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 STAMFORD, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medicare & M...
SWK Holdings (NASDAQ:SWKH) wholly-owned subsidiary, Enteris BioPharma received a $5M milestone payment from Cara Therapeutics (NASDAQ:CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA. Enteris is entitled to retain $3M of t...
STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid...
STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...
Cara Therapeutics, Inc. (CARA) Q3 2021 Earnings Conference Call November 08, 2021 4:30 PM ET Company Participants William Gramig - Stern Investor Relations Derek Chalmers - President and Chief Executive Officer Christopher Posner - Incoming CEO Thomas Reilly - Chief Financial Officer Conferen...
Cara Therapeutics (NASDAQ:CARA) shares rose more than 10% post market after the company reported third-quarter earnings that beat Wall Street estimates and provided an update on its cash position. Quarterly revenue more than doubled to $20.27M, beating analysts' average estimat...
Cara Therapeutics (NASDAQ:CARA): Q3 GAAP EPS of -$0.02 beats by $0.40. Revenue of $20.27M (+118.7% Y/Y) beats by $9.06M. Press Release Cash, cash equivalents and marketable securities at September 30, 2021 totaled $193.4 million compared to $251.5 million at December 31, 2020. Financial...
– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) – – Christopher Posner Appointed Presiden...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...